- This event has passed.
International Masterclass | Is Atopic Dermatitis Only Skin Deep? With Prof Stephan Weidinger
20 March @ 6:30 pm - 8:00 pm
Free
Overview
This Masterclass featuring renowned international speaker Prof Stephan Weidinger, and chaired by A/Prof Peter Foley, will delve into the intricate aspects of atopic dermatitis (AD) beyond the confines of clinical trials, emphasising the importance of longer-term data in shaping decision-making and treatment choices.
Prof Weidinger will explore long-term data implications on informing effective treatment strategies. He will also share and discuss real-world data from the German AD registry and AD registries from around the world.
We invite you to join us for this informative online Masterclass followed by a Q&A session.
Prof Stephan Weidinger
MD PhD
Stephan Weidinger is currently Professor and Chair for Dermatology at the Christian-Albrechts-University as well as Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, Campus Kiel, Germany. He qualified as a physician from the University of Regensburg, Germany, and following this he received his MD and PhD from the Technische Universität in Munich, Germany. Prior to his current position, Professor Weidinger held a senior physician position at the Department of Dermatology and Allergy, Technische Universität Munich, where he led the inflammatory skin disease unit.
In addition to his clinical and research roles, Professor Weidinger is an Associate Editor of the Journal of Allergy and Clinical Immunology and the British Journal of Dermatology, and Editorial Board member of the Journal of Investigative Dermatology and the Journal of the European Academy of Dermatology and Venereology.
Professor Weidinger’s main research interests lie in the molecular mechanisms and treatment of allergic and chronic inflammatory skin diseases, in particular atopic dermatitis, and he has published numerous peer-reviewed publications on this and other related topics.
He is coordinator of the international BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) consortium funded by the European Union’s Horizon 2020 research and innovation programme and EFPIA, is involved in the EU/IMI ImmUniverse project, is principal investigator in the German Excellence Cluster “Precision Medicine in Inflammation” and of the German atopic dermatitis registry TREATGermany, and is involved in multiple clinical trials on atopic dermatitis, hand eczema and alopecia areata.
Professor Weidinger has also been presented with multiple awards including the Langerhans Award of the German Society for Dermatological Research (ADF), the PhARF (Phadia Allergy Research Forum) Award, the European Centre for Allergy Research Foundation (ECARF) Award, the Allergopharma Award, a Heisenberg fellowship of the German Research Council, and the Herxheimer Award of the German Society for Allergy and Clinical Immunology.
A/Prof Peter Foley
MBBS FACD
Associate Professor Peter Foley is the Director of Research at the Skin Health Institute and the Head of Dermatology Research at St Vincent’s Hospital Melbourne. He currently holds the position of Associate Professor, Department of Medicine at The University of Melbourne. He is a Visiting Medical Officer to the Photobiology, Dermatology Biologics, and Dermatology Investigation clinics at St Vincent’s Hospital Melbourne and the Phototherapy, Atopic Dermatitis, and Psoriasis Advanced Targeted Therapies clinics at the Skin Health Institute.
He has been an investigator in over 160 clinical trials, including trials for dupilumab, tralokinumab, lebrikizumab, nemolizumab, amlitelimab, rocatinlimab, baricitinib, upadacitinib and abrocitinib in atopic dermatitis, and has over 160 published manuscripts.
A/Prof Foley is Australia’s only councillor on the International Psoriasis Council (IPC), is a founding member of the Australasian Psoriasis Collaboration, is co-convener of the Australasian Dermatology Registry, and is chair of the steering committee for the Pillars of Dermatology Practice Symposium. Additionally, he is a part of the ‘treat to target project’ in atopic dermatitis, and co-authored ‘Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative’, ‘Atopic dermatitis in adults: An Australian management consensus, and Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting’.
